Sign In
test

Ryan Cappelli

Prosight Management, Lp

Assets Managed
$609.82M
Holdings
46
Last Quarter
2026 - Q1
Filed Date
1mo 4d ago
Growth Rate
26.02%(2Q avg: 19.44%)
Sustained Growth
4 quarters

Portfolio positions

This chart displays the top 10 holdings in Prosight Management, Lp's 2026 - Q1 portfolio, based on their 13F SEC filing, out of a total of 46 positions.

Assets under management

The assets under management (AUM) of Prosight Management, Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 4 quarters. As of the latest 13F SEC filing for 2026 - Q1, they manage 609.82M in assets, with a quarterly growth rate of 26.02% and a 2-quarter average growth rate of 19.44%. The portfolio is managed by Ryan Cappelli, and others.

Portfolio holdings

InvestmentPortfolio %Reported Value
NKTR
Nektar Therapeutics
Recent Activity
Increased 32.53%
8.68%
$52.883M
735,000 shares@ $71.95 avg price
BSX
Boston Scientific Corp
Recent Activity
Increased 278.84%
8.19%
$49.921M
795,547 shares@ $62.75 avg price
JANX
Janux Therapeutics Inc
Recent Activity
Increased 48.38%
8.1%
$49.345M
3.55M shares@ $13.9 avg price
PRCT
Procept Biorobotics Corp
Recent Activity
Increased 40.95%
7.98%
$48.644M
1.945M shares@ $25.01 avg price
GLPG
Galapagos Nv-spon Adr
Recent Activity
Increased 44.31%
7.63%
$46.5M
1.55M shares@ $30.0 avg price
WGS
Genedx Holdings Corp
Recent Activity
Increased 851.76%
5.52%
$33.617M
523,463 shares@ $64.23 avg price
STTK
Shattuck Labs Inc
Recent Activity
Increased 110.14%
5.28%
$32.179M
5.004M shares@ $6.44 avg price
ADCT
Adc Therapeutics Sa
Recent Activity
Decreased -2.09%
5.11%
$31.125M
8.3M shares@ $3.75 avg price
KURA
Kura Oncology Inc
Recent Activity
Increased 32.7%
4.48%
$27.29M
3.357M shares@ $8.13 avg price
ALNY
Alnylam Pharmaceuticals Inc
Recent Activity
Increased 344.22%
4.13%
$25.146M
76,000 shares@ $330.87 avg price

1-10 of 46